4 registrations that name acacia Fiber as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
All 4 registrations
RecruitingNCT04578652
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Phase 3
University of Alberta
About 90 people
Started Oct 22, 2021
In plain words A Phase 3 study of acacia Fiber in people 12 to 18, run by University of Alberta. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 18. Conditions: Obesity, Childhood; Insulin Resistance.
Age 12-18 years
BMI percentile > 95% for age/sex;
Total weight fluctuation over past 6 months < 10%;
HOMA-IR > 3.16;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Metformin 850 mg oral tablet bid; Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
Registered summary
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06515210
Personalized Anti-Inflammatory Fibres in Ulcerative Colitis
No phase
University of Alberta
About 69 people
Started Jun 3, 2025
In plain words A study of acacia Fiber in people 14 and older, run by University of Alberta. It plans to enroll about 69 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 14 and older. Conditions: Ulcerative Colitis.
Known diagnosis of ulcerative colitis.
Evidence of active disease, defined as either 1) measured FCP >100 µg/g at screening, OR 2) Partial Mayo Scoring Index Assessment for UC ≥2 (adult patients) OR Pediatric UC Activity Index (PUCAI) ≥10 (pediatric patients).
Tanner stage ≥4 for pediatric patients.
Weight >40kg.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Acacia Gum; Microcrystalline Cellulose; Placebo
Registered summary
The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients with ulcerative colitis. The main question it aims to answer is: Can the fibre supplements reduce gut inflammation (fecal calprotectin)? Researchers will compare AG and MCC to a placebo (a look-alike substance that contains no fibre) to see if the fibre supplements improve inflammation in ulcerative colitis. Participants will add their assigned fibre supplement or placebo to their usual diet daily for 6 weeks. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06836206
The Effect of Gum Arabic (GA) on Residual Renal Function in Adult Dialysis Patients in Abu Dhabi
Phase 1 and 2
Abu Dhabi Health Services Company
About 40 people
Started Feb 3, 2025
In plain words A Phase 1 and 2 study of acacia Fiber in people 18 and older, run by Abu Dhabi Health Services Company. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: End Stage Renal Disease (ESRD).
Men and women ≥18 years of age with diagnosed ESRD and prescribed regular dialysis at least once a week, weekly at least for past two weeks.
For past two weeks including women of childbearing potential who are currently adopting any method of contraception or have completed the family and undergone sterilization procedures and women of non-childbearing potential.
Patients with residual renal function - Patients who produce a minimum of 200 ml of urine during a full day of collection (A full day collection: the patient discards the first urine sample on the day of collection then collects all urine…
Able and willing to complete the whole period of the study (maximum of 266 days from enrolment).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Gum Arabic; Water
Registered summary
Gum Arabic (GA), derived from Acacia trees, has shown potential benefits in metabolic, renal, and inflammatory conditions. This study explores the impact of GA on residual renal function in end-stage renal disease (ESRD) patients undergoing dialysis, as current evidence is limited.
Where, as registered
No US site; United Arab Emirates (1).
Not yet recruitingNCT07703254
A Clinical Trial to Investigate the Efficacy of Acacia Fiber on Gastrointestinal Health and Microbiota Composition in Healthy Adults With Occasional Constipation
No phase
Nexira
About 105 people
Starts Jul 2026 (estimated)
In plain words A study of acacia Fiber in people 30 to 60, run by Nexira. It plans to enroll about 105 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 60; healthy volunteers accepted. Conditions: Occasional Constipation; Gastrointestinal Health; Gut Microbiota Composition.
Males and females aged between 30 and 60 years old, inclusive
Body Mass Index (BMI) between 18.5 to 29.9 kg/m², inclusive
Stable body weight defined as a <5% change in body weight in the three months prior to baseline as assessed by the Qualified Investigator (QI)
Participants must meet the following criteria of occasional constipation for the past 3 months. This will be assessed at screening and confirmed over a 2-week period prior to baseline:
7 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this randomized blinded placebo-controlled clinical trial is to investigate the effect of low- and high-dose supplementation of Acacia fiber on gut health and microbiota composition in adults with occasional constipation in a controlled diet context. Acacia fiber is a soluble dietary fiber with prebiotic properties, and this study evaluates its role in modulating gut microbiota and associated gastrointestinal outcomes. The full summary is on the listing.